FLT3 and acute myeloid leukemia: To further evaluate dominant mutational clones in non-APL AML, we defined a mutation as dominant when either (1) it was the sole mutation detected (e.g., WT1, DNMT3A, or FLT3 in three patients each) or (2) it displayed a variant allele frequency (VAF) at least 10% higher than other co-occurring mutations.